Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Stock Price Up 6.9% – What’s Next?

Posted by Stanley Muller on Apr 16th, 2026

Shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Get Free Report) rose 6.9% during trading on Wednesday . The stock traded as high as $0.5299 and last traded at $0.5080. Approximately 311,928 shares traded hands during mid-day trading, a decline of 8% from the average daily volume of 339,875 shares. The stock had previously closed at $0.4750.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research note on Friday, April 10th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Inspira Technologies OXY B.H.N. currently has an average rating of “Hold” and a consensus target price of $2.00.

Check Out Our Latest Stock Analysis on IINN

Inspira Technologies OXY B.H.N. Trading Up 6.9%

The stock’s fifty day simple moving average is $0.55 and its two-hundred day simple moving average is $0.84. The company has a quick ratio of 1.30, a current ratio of 1.56 and a debt-to-equity ratio of 0.08.

Hedge Funds Weigh In On Inspira Technologies OXY B.H.N.

A number of hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new position in shares of Inspira Technologies OXY B.H.N. in the 4th quarter valued at $71,000. Yorkville Advisors Global LP acquired a new position in shares of Inspira Technologies OXY B.H.N. in the 4th quarter valued at $1,605,000. Finally, Citadel Advisors LLC acquired a new position in shares of Inspira Technologies OXY B.H.N. in the 3rd quarter valued at $105,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

About Inspira Technologies OXY B.H.N.

(Get Free Report)

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.